Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGPAT2 | O15120 | 2/20 | 0.38 |
| ▸ | CRHR1 | P34998 | 13/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
| ▸ | TACR3 | P29371 | 1/20 | 0.35 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24073578 | 1.00 | AGPAT2 (0.38) | AGPAT2CRHR1MEN1KMT2ATACR1 | |
| SCHEMBL31017677 | 1.00 | AGPAT2 (0.38) | AGPAT2CRHR1MEN1KMT2ATACR1 | |
| SCHEMBL24072840 | 1.00 | AGPAT2 (0.38) | AGPAT2CRHR1MEN1KMT2ATACR1 | |
| SCHEMBL24073580 | 1.00 | AGPAT2 (0.38) | AGPAT2CRHR1MEN1KMT2ATACR1 | |
| SCHEMBL27418620 | 1.00 | AGPAT2 (0.38) | AGPAT2CRHR1MEN1KMT2ATACR1 | |
| SCHEMBL24073663 | 0.91 | LCLAT1 (0.34) | — | |
| SCHEMBL30370285 | 0.91 | LCLAT1 (0.34) | — | |
| SCHEMBL30370549 | 0.91 | LCLAT1 (0.34) | — | |
| SCHEMBL24072856 | 0.91 | LCLAT1 (0.34) | — | |
| SCHEMBL25837893 | 0.89 | AGPAT2 (0.36) | AGPAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4157834-B1 | N-(1-CYANO-PYRROLIDIN-3-YL)-5-(3-(TRIFLUOROMETHYL)PHENYL)OXAZOLE-2-CARBOXAMIDE DERIVATIVES AND THE CORRESPONDING OXADIAZOLE DERIVATIVES AS USP30 INHIBITORS FOR THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION | MISSION THERAPEUTICS LTD (GB) | 2024-07-03 | — | — | EP | claimed |
| EP-4157834-A1 | N-(1-CYANO-PYRROLIDIN-3-YL)-5-(3-(TRIFLUOROMETHYL)PHENYL)OXAZOLE-2-CARBOXAMIDE DERIVATIVES AND THE CORRESPONDING OXADIAZOLE DERIVATIVES AS USP30 INHIBITORS FOR THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION | Mission Therapeutics Limited (GB) | 2023-04-05 | — | — | EP | claimed |
| EP-4157834-B1 | N-(1-CYANO-PYRROLIDIN-3-YL)-5-(3-(TRIFLUOROMETHYL)PHENYL)OXAZOLE-2-CARBOXAMIDE DERIVATIVES AND THE CORRESPONDING OXADIAZOLE DERIVATIVES AS USP30 INHIBITORS FOR THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION | MISSION THERAPEUTICS LTD (GB) | 2024-07-03 | — | — | EP | disclosed |
| EP-4157834-A1 | N-(1-CYANO-PYRROLIDIN-3-YL)-5-(3-(TRIFLUOROMETHYL)PHENYL)OXAZOLE-2-CARBOXAMIDE DERIVATIVES AND THE CORRESPONDING OXADIAZOLE DERIVATIVES AS USP30 INHIBITORS FOR THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION | Mission Therapeutics Limited (GB) | 2023-04-05 | — | — | EP | disclosed |